GlassScriptPhysician profile
Stephen S Nagy
NPI 1538123161
$4,842.68
in general payments reported to CMS, 2019-2025
26 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $401 · 2021: $613 · 2022: $998 · 2023: $510 · 2024: $1,168 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.75 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,205.89 | 2019-2025 | Ngenuity, Clareon, Centurion |
| Allergan, INC. | $580.05 | 2019-2021 | |
| Abbvie INC. | $311.16 | 2022-2025 | |
| Rxsight INC | $250.58 | 2022-2025 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Sight Sciences, INC. | $189.00 | 2019-2025 | Omni Surgical System |
| Ocular Therapeutix, INC. | $169.64 | 2023-2025 | Dextenza |
| Harrow Eye, LLC | $161.06 | 2025 | Vevye, Iheezo |
| Omeros Corporation | $139.71 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $119.29 | 2022-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Johnson & Johnson Surgical Vision, INC. | $105.20 | 2020-2021 | |
| Dompe US, INC. | $100.15 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $69.23 | 2020-2021 | |
| Horizon Therapeutics Plc | $60.06 | 2021-2022 | |
| Glaukos Corporation | $46.22 | 2019 | |
| Sun Pharmaceutical Industries INC. | $45.49 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $43.92 | 2023-2024 | Miebo, Vyzulta |
| Amgen INC. | $43.47 | 2024-2025 | Tepezza |
| Acacia Pharma INC | $43.13 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $35.37 | 2024 | Exparel |
| Ivantis, INC | $24.35 | 2019-2020 | |
| Heron Therapeutics, INC. | $19.88 | 2024 | Zynrelef |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Boston Scientific Corporation | $18.77 | 2024 | Wavewriter Alpha Prime 16 |
| Eyepoint US, INC. | $16.55 | 2019 | |
| Biotissue Holdings INC. | $13.99 | 2025 | |
| New World Medical,INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Nagy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.